We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Metabolites of Tear Fluid (Metabol-T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03389282
Recruitment Status : Recruiting
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
Institute of Ophthalmic Research Tuebingen
Institute for Clinical Epidemiology and Applied Biometry Tuebingen
Information provided by (Responsible Party):
University Hospital Tuebingen

Brief Summary:
The pilot trial evaluates the use of modified Schirmer strips and is designed to evaluate inter-individual range of metabolites in tear film.

Condition or disease Intervention/treatment
Healthy Subjects Diagnostic Test: Tear Sampling

Detailed Description:

The variability of tear film metabolites should be investigated in a sample of ophthalmologists in preparation for a pilot study in patients eye diseases.

The easy accessibility of the tear fluid and the lack of invasiveness of the study make it promising and sensible to determine the concentration of various tear film metabolites. Because attention has so far focused primarily on the quantitative and qualitative analysis of tear film proteins, many metabolites have so far only been shown to be contained in tears.

However, before the suitability of the measured values as a predictive parameter of the ocular surface for pathologies can be examined and assessed, it is necessary to determine the scattering variables in a sample of healthy volunteers. Thus, reference areas are to be defined for later investigations in order to enable reliable case number planning thereafter.

Repeated determinations at different times and on different days make it possible in particular to detect a time-dependent relationship in view of the dynamic variability of the tear film. The functional significance of certain metabolites can not yet be assessed in the establishment phase. However, the data may provide important information for the interpretation of a later, planned feasibility study with diseased patients or the influence of applied eye drops.

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Metabolites of Tear Fluid - Evaluation in a Clinical Pilot Study
Actual Study Start Date : November 1, 2013
Primary Completion Date : December 1, 2016
Estimated Study Completion Date : April 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tears
U.S. FDA Resources

Intervention Details:
    Diagnostic Test: Tear Sampling
    comprehensive eye exam, Schirmer test, break-up time, tear sampling

Primary Outcome Measures :
  1. concentration of analytes (lipids, proteins/amino acids) [ Time Frame: 3 days per patient ]
    level of analytes (ng/ml)

  2. number of detecatable analytes [ Time Frame: 3 days per patient ]
    number of analytes (lipds, proteins/amino acids)

Biospecimen Retention:   Samples Without DNA
Tear fluid

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
healthy volunteers without any eye condition and normal anterior surface

Inclusion Criteria:

  • healthy subjects at age > 18 years

Exclusion Criteria:

  • in the case of subjects with a mental disability or legal guardianship, due to possible conflicts for the caregivers, a data evaluation and recording should in principle be dispensed with.
  • subjects who have had any eye drops within the last 4 weeks, e.g. lubricants were used
  • subjects undergoing clinical examination for symptoms of wetting disorder or morphological changes related to eye disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03389282

Contact: Focke Ziemssen, MD +49 7071 29 84762 focke.ziemssen@med.uni-tuebingen.de
Contact: Sascha Dammeier, PhD +49 7071 29 84955 sascha.dammeier@uni-tuebingen.de

University Eye Hospital Recruiting
Tuebingen, BW, Germany, 72076
Contact: Focke Ziemssen, MD    0049 7071 29 84761    Focke.Ziemssen@med.uni-tuebingen.de   
Principal Investigator: Focke Ziemssen, MD         
Sponsors and Collaborators
University Hospital Tuebingen
Institute of Ophthalmic Research Tuebingen
Institute for Clinical Epidemiology and Applied Biometry Tuebingen
Principal Investigator: Focke Ziemssen, MD Center for Ophthalmology, University of Tuebingen

Responsible Party: University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT03389282     History of Changes
Other Study ID Numbers: AZ 277/2013BO2
First Posted: January 3, 2018    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital Tuebingen:
Tear, Metabolite